Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study.

Autor: Sampani K; Beetham Eye Institute, Joslin Diabetes Center, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Ness S; Department of Ophthalmology, Boston Medical Center, Boston, MA, 02118, USA.; Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA., Tuz-Zahra F; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA., Aytan N; Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Spurlock EE; Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Alluri S; Department of Ophthalmology, Boston Medical Center, Boston, MA, 02118, USA., Chen X; Department of Ophthalmology, Boston Medical Center, Boston, MA, 02118, USA.; Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA., Siegel NH; Department of Ophthalmology, Boston Medical Center, Boston, MA, 02118, USA.; Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA., Alosco ML; Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.; Department of Psychology, University of Arizona, Tucson, AZ, USA., Xia W; Department of Pharmacology and Experimental Therapeutics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.; Geriatric Research Education and Clinical Center, Bedford Veterans Affairs Medical Center, Bedford, MA, USA., Tripodis Y; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.; Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Stein TD; Boston University Alzheimer's Disease Research Center and CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA. tdstein@bu.edu.; Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA. tdstein@bu.edu.; Department of Veterans Affairs Medical Center, VA Boston Healthcare System, Boston, MA, USA. tdstein@bu.edu.; Department of Veterans Affairs Medical Center, VA Bedford Healthcare System, Bedford, MA, USA. tdstein@bu.edu., Subramanian ML; Department of Ophthalmology, Boston Medical Center, Boston, MA, 02118, USA. manju.subramanian@bmc.org.; Department of Ophthalmology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. manju.subramanian@bmc.org.
Jazyk: angličtina
Zdroj: Alzheimer's research & therapy [Alzheimers Res Ther] 2024 Aug 26; Vol. 16 (1), pp. 192. Date of Electronic Publication: 2024 Aug 26.
DOI: 10.1186/s13195-024-01556-y
Abstrakt: Background: Protein biomarkers have been broadly investigated in cerebrospinal fluid and blood for the detection of neurodegenerative diseases, yet a clinically useful diagnostic test to detect early, pre-symptomatic Alzheimer's disease (AD) remains elusive. We conducted this study to quantify Aβ40, Aβ42, total Tau (t-Tau), hyperphosphorylated Tau (ptau181), glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) in eye fluids relative to blood.
Methods: In this cross-sectional study we collected vitreous humor, aqueous humor, tear fluid and plasma in patients undergoing surgery for eye disease. All six biomarkers were quantitatively measured by digital immunoassay. Spearman and Bland-Altman correlation analyses were performed to assess the agreement of levels between ocular fluids and plasma.
Results: Seventy-nine adults underwent pars-plana vitrectomy in at least one eye. Of the 79, there were 77 vitreous, 67 blood, 56 tear fluid, and 51 aqueous samples. All six biomarkers were quantified in each bio-sample, except GFAP and NfL in tear fluid due to low sample volume. All six biomarkers were elevated in vitreous humor compared to plasma samples. T-Tau, ptau181, GFAP and NfL were higher in aqueous than in plasma, and t-Tau and ptau181 concentrations were higher in tear fluid than in plasma. Significant correlations were found between Aβ40 in plasma and tears (r = 0.5; p = 0.019), t-Tau in plasma and vitreous (r = 0.4; p = 0.004), NfL in plasma and vitreous (r = 0.3; p = 0.006) and plasma and aqueous (r = 0.5; p = 0.004). No significant associations were found for Aβ42, ptau181 and GFAP among ocular fluids relative to plasma. Bland-Altman analysis showed aqueous humor had the closest agreement to plasma across all biomarkers. Biomarker levels in ocular fluids revealed statistically significant associations between vitreous and aqueous for t-Tau (r = 0.5; p = 0.001), GFAP (r = 0.6; p < 0.001) and NfL (r = 0.7; p < 0.001).
Conclusion: AD biomarkers are detectable in greater quantities in eye fluids than in plasma and show correlations with levels in plasma. Future studies are needed to assess the utility of ocular fluid biomarkers as diagnostic and prognostic markers for AD, especially in those at risk with eye disease.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje